Ocrevus subcutaneous maintains consistent benefit-risk profile after two years -- New late-breaking data confirms Ocrevus significantly reduces disability progression in adults with advanced PPMS -- ...
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that its t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID ...
The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis.
SurvivorNet on MSN
FDA Approves New Subcutaneous (Under-the-Skin) Option for Keytruda: What It Means for Cancer Patients
The U.S. Food and Drug Administration (FDA) has approved the subcutaneous form of Keytruda for a new 'Under-the-Skin' Option for patients. The subcutaneous form of Keytruda showed to deliver the same ...
The weekly combination therapy is intended for adults with poor glucose control despite basal insulin or GLP-1 receptor agonist treatment.
ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple ...
Objectives Gout is a common disease causing excruciatingly painful and disabling flares. Although currently approved treatments for gout flares are generally effective, their use is restricted in many ...
MyChesCo on MSN
FDA Approves Johnson & Johnson’s Tremfya Subcutaneous Induction for Ulcerative Colitis
HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has approved a subcutaneous induction regimen of TREMFYA (guselkumab) for the treatment of adults ...
The FDA has expanded the approval of Tremfya (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis (UC) to include an SC induction regimen.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback